VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Required: NTRK1 fusion

any NTRK1 gene fusion positive ("NTRK1+") solid tumors or lymphomas

Required: NTRK1 overexpression

TrkA-driven HNC, Esophageal, Lung, Mesothelioma, Pancreatic cancers

Must have received: standard of care — relapsed, refractory or intolerant (R/R/I) to SOC and for which there is no approved or curative therapy

relapsed, refractory or intolerant (R/R/I) to standard of care (SOC) and for which there is no approved or curative therapy. Additionally, patients must not be candidates for or have exhausted regimens known to provide clinical benefit, including hematopoietic stem cell transplantation in lymphoma patients if they are deemed transplant eligible.

Cannot have received: chemotherapy with delayed toxicity (nitrosourea, mitomycin C)

Received chemotherapy having delayed toxicity within the last 14 days (six weeks for prior nitrosourea or mitomycin C).

Cannot have received: anticancer therapy (radiation, immunotherapy, biologic, surgery, tumor embolization)

Received anticancer therapy with radiation, immunotherapy, and a biologic, surgery and/or tumor embolization within the past 2 weeks.

Cannot have received: investigational anticancer drug

Received an investigational anticancer drug within 14 days or 5 half-lives of the investigational agent, whichever is longer, prior to the first dose of VMD-928.